Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya ...

Basel, 30 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity ...

MagnetOs MIS sets a new standard in minimally invasive surgery as the only bone graft delivery system that is sterile, prefilled, free of human tissue, and with a mechanism of action backed by Level I ...

Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders ...

SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will ...

The webcast presentation will take place at 5:00 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or ...

The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or ...

Upon completion, Biopharma Co will be a clinical-stage biotechnology company focused on the development and potential commercialization of innovative therapeutics for autoimmune and inflammatory ...

The employees received, in the aggregate, nonqualified options to purchase 299,200 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent ...

This agreement also contemplates a commitment by N2OFF to financially support MitoCareX’s operations during the first two years following the closing, including an initial cash investment of ...

Based on these positive topline data, Metsera is on track to initiate a global Phase 3 program in late 2025. Additional Phase 2b trials are ongoing to characterize the monthly profile of MET-097i for ...

uniQure intends to use the net proceeds from this offering to fund its commercialization readiness activities, the potential commercial launch of AMT-130 and related commercialization activities, the ...